Biocon has reported results for first quarter ended June 30, 2014.
The company’s net profit has declined 14.93% at Rs 74.63 crore as compared to Rs 87.73 crore for the quarter ended June 30, 2013. Its total income has decreased by 0.31% to Rs 570.43 crore for the quarter under review from Rs 572.22 crore for the corresponding quarter of the previous year.
On the consolidated basis, the Group has reported 10.06% rise in its net profit after taxes & Minority interest at Rs 102.91 crore for the quarter as compared to Rs 93.50 crore for the same quarter in the previous year. Total income has increased by 2.59% at Rs 741.95 crore for quarter under review as compared to Rs 723.17crore for the quarter ended June 30, 2013.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: